These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. Chang TT; Lêng CH; Wu JY; Lee SY; Wang YS; Chen YC; Lu RB Chin J Physiol; 2008 Dec; 51(6):387-93. PubMed ID: 19280883 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition. Ushiroyama T; Ikeda A; Ueki M J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873 [TBL] [Abstract][Full Text] [Related]
26. Patient satisfaction with antidepressants: an Internet-based study. Shigemura J; Sato Y; Yoshino A; Nomura S J Affect Disord; 2008 Apr; 107(1-3):155-60. PubMed ID: 17881062 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836 [TBL] [Abstract][Full Text] [Related]
28. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Takahashi H; Kamata M; Yoshida K; Higuchi H; Shimizu T Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):351-3. PubMed ID: 15694247 [TBL] [Abstract][Full Text] [Related]
29. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Obata H; Saito S; Koizuka S; Nishikawa K; Goto F Anesth Analg; 2005 May; 100(5):1406-1410. PubMed ID: 15845695 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic effects of milnacipran (serotonin noradrenalin reuptake inhibitor) on depression following mild and moderate traumatic brain injury. Kanetani K; Kimura M; Endo S J Nippon Med Sch; 2003 Aug; 70(4):313-20. PubMed ID: 12928711 [TBL] [Abstract][Full Text] [Related]
32. Raynaud's syndrome in a patient treated with milnacipran. Bourgade B; Jonville-Béra AP; Le Garé C; Ferquel D; Autret-Leca E Ann Pharmacother; 1999 Sep; 33(9):1009-10. PubMed ID: 10492510 [No Abstract] [Full Text] [Related]
33. Stimulation of catecholamine synthesis via activation of p44/42 MAPK in cultured bovine adrenal medullary cells by milnacipran. Shinkai K; Toyohira Y; Yoshimura R; Tsutsui M; Ueno S; Nakamura J; Yanagihara N Naunyn Schmiedebergs Arch Pharmacol; 2007 Mar; 375(1):65-72. PubMed ID: 17211600 [TBL] [Abstract][Full Text] [Related]
34. [SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine]. Rusconi AC; Carlone C; Muscillo M; Coccanari de' Fornari MA; Podda L; Piccione M Riv Psichiatr; 2009; 44(5):313-9. PubMed ID: 20066819 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of milnacipran on the depressive state in patients with Alzheimer's disease. Mizukami K; Tanaka Y; Asada T Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1342-6. PubMed ID: 16603301 [TBL] [Abstract][Full Text] [Related]
36. Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm. Miyamoto J; Tsuji M; Takeda H; Ohzeki M; Nawa H; Matsumiya T Eur J Pharmacol; 2004 Nov; 504(1-2):97-103. PubMed ID: 15507225 [TBL] [Abstract][Full Text] [Related]
37. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265 [TBL] [Abstract][Full Text] [Related]
38. Treatment of verbal agitation with a selective serotonin reuptake inhibitor. Ramadan FH; Naughton BJ; Bassanelli AG J Geriatr Psychiatry Neurol; 2000; 13(2):56-9. PubMed ID: 10912725 [TBL] [Abstract][Full Text] [Related]
39. Serotonin agents in the treatment of acquired brain injury. Zafonte RD; Cullen N; Lexell J J Head Trauma Rehabil; 2002 Aug; 17(4):322-34. PubMed ID: 12106001 [TBL] [Abstract][Full Text] [Related]
40. Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Ito M; Kimura H; Yoshida K; Kimura Y; Ozaki N; Kurita K Clin Neuropharmacol; 2010; 33(2):79-83. PubMed ID: 20375656 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]